MedTrace Logo

Palladium-103 Seed Implant and Single Daily Dosing of Uroxatral Vs. Twice Daily Dosing of Flomax- A 3 Month Retrospective Efficacy Analysis

NCT00264017 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2005-12-12

No results posted yet for this study

Summary

In the past ten years, newer drugs with more selective affinity for the alpha-receptor have been introduced. Alfuzosin (Uroxatral) and Tamulosin(Flomax are two second generation alpha-blockers. In the course of our clinical proctice, both drugs have been used routinely. This retrospective comparison is intended to be a priliminary comparison of their effectiveness and side effects.

Conditions

  • Prostate Cancer Patients Undergoing External Radiation and Seed Implantation

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • Dattoli Cancer Center and Brachytherapy Research Institute

    lead OTHER

Principal Investigators

  • Michael J Dattoli, MD · Dattoli Cancer Center and Brachytherapy Research Institute

Eligibility

Min Age
45 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Completion
2005-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00264017 on ClinicalTrials.gov